Form 4 Praxis Precision Medicines Inc: Alex Nemiroff (General Counsel and Secretary) For: 13 November
This article reports on a Form 4 filing for Praxis Precision Medicines Inc., specifically detailing a transaction involving Alex Nemiroff, the General Counsel and Secretary, on November 13. The brief announcement provides no further details about the nature of the transaction. The article includes standard financial market data and navigation links.
Megan Sniecinski acquired 21 shares of Praxis Precision Medicines (PRAX) through its employee stock purchase plan.
Praxis Precision Medicines COO Megan Sniecinski acquired 21 common shares on November 13, 2026, through the company's Employee Stock Purchase Plan at a price of $278.9110 per share. This transaction increased her direct holdings to 28,685 shares and was exempt under SEC Rules 16b-3(d) and 16b-3(c). The filing was accepted by the SEC EDGAR system on November 18, 2026, at 08:39 PM EST.
Form 4 Praxis Precision Medicines Inc: Timothy Edwin Kelly (CFO) For: 13 November
This article reports a Form 4 filing for Praxis Precision Medicines Inc., concerning a transaction by Timothy Edwin Kelly (CFO) on November 13. The company's stock symbol is PRAX, and it showed a 1.87% gain.
Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $592
Goldman Sachs has reiterated its Buy rating on Praxis Precision Medicines (PRAX.US) and increased its price target to $592. This adjustment reflects the firm's continued confidence in the company's prospects.
Praxis CEO Marcio Souza: Two FDA Decisions and a $100,000-a-Year Bet on Going It Alone
Praxis Precision Medicines is awaiting two crucial FDA decisions for its drugs, ulixacaltamide for essential tremor and relutrigine for epilepsy, by early 2027. CEO Marcio Souza plans to commercialize both drugs independently, projecting an annual US price of $50,000 to $100,000 for ulixacaltamide in a market with over two million patients. While confident about ulixacaltamide's approval, Souza notes more "nuanced discussions" for relutrigine, with its broader potential hinging on the EMERALD trial.
Wells Fargo Upgrades Praxis Precision Medicines(PRAX.US) to Buy Rating, Raises Target Price to $509
Wells Fargo analyst Benjamin Burnett has upgraded Praxis Precision Medicines (PRAX.US) to a buy rating, significantly increasing the target price from $343 to $509. This upgrade reflects a positive outlook on the company, although TipRanks data indicates the analyst has a historical success rate of 35.5% and an average return of -6.7% over the past year.
Praxis Precision Medicines upgraded by Wells Fargo with a new price target
Wells Fargo has upgraded Praxis Precision Medicines (PRAX) to Overweight from Equal Weight, setting a new price target of $509.00. This analyst rating change was delivered by Quantisnow, a real-time market data platform. Historical data shows that PRAX stock has had varied responses to previous headlines, with a median move of 3.9% after earlier news.
Wells Fargo upgrades Praxis Precision Medicines stock rating on endpoint confidence
Wells Fargo upgraded Praxis Precision Medicines (NASDAQ:PRAX) from Equal Weight to Overweight, raising its price target to $509 from $343 due to increased confidence in the primary endpoint for the company's ulixa drug candidate. Analyst Ben Burnett noted that the firm's concerns about the endpoint's robustness and the alternative titration protocol were alleviated after discussions with statisticians and reviewing additional analyses shared with the FDA. This positive sentiment is echoed by other analysts who have also raised price targets for Praxis, citing strong pipeline potential.
Two investors report 1.36M Praxis Precision Medicines (PRAX) shares but disclaim group status.
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have filed an amended beneficial-ownership report for Praxis Precision Medicines, Inc. (PRAX). Together, they reported owning 1,360,049 shares, representing 4.9% of the class, with Orbis holding the vast majority. Both firms disclaimed being part of a group under Section 13(d)(3) and each disclaimed beneficial ownership of shares held by the other.
Guggenheim raises Praxis Precision Medicines price target to $1,050 By Investing.com
Guggenheim has increased its price target for Praxis Precision Medicines Inc. (NASDAQ:PRAX) to $1,050 from $800, maintaining a Buy rating, citing over $20 billion in peak sales potential across four assets. The primary driver is Ulixacaltamide, with a PDUFA date of January 29, 2027, and strong long-term data. Other firms, including H.C. Wainwright and Raymond James, have also reiterated positive ratings and raised price targets for Praxis, highlighting the company's promising pipeline.
Baird Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $568
Baird has reiterated its "Buy" rating for Praxis Precision Medicines (PRAX.US) and has increased its price target to $568. This indicates a positive outlook from the analyst firm regarding the company's future performance and stock valuation.
Praxis Precision Medicines rated Strong Buy with $601 fair value, FDA decision on key drug in January is pivotal.
Analyst Zbigniew Budzinski maintains a Strong Buy rating on Praxis Precision Medicines (PRAX) with a fair value of $601 per share. The upcoming FDA decision in January on the drug Ulixacaltamide is a critical risk factor, with approval potentially raising the stock value significantly, while rejection could lead to a substantial drop. Additional upside is anticipated from the EMERALD program, though initial sales may face payer access challenges.
RBC Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $478
RBC Capital has reiterated its Buy rating on Praxis Precision Medicines (PRAX.US) and maintained its target price at $478. This indicates continued confidence in the company's prospects and valuation by the investment firm.
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
Praxis Precision Medicines hosted its Investor Day, detailing launch readiness for relutrigine in SCN2A and SCN8A DEEs and ulixacaltamide in essential tremor, with PDUFA target action dates in late 2026 and early 2027. The company also unveiled plans to expand ulixacaltamide into Parkinson’s disease, Restless Legs Syndrome, and Autism Spectrum Disorder, alongside a broadened pipeline in pain and rare epilepsies. These strategic moves aim to position Praxis as a leading CNS biopharmaceutical company.
Form 8K Praxis Precision Medicines Inc For: 12 November By Investing.com
Praxis Precision Medicines Inc. filed a Form 8K on November 12, 2026. This filing is a regulatory document often used to announce significant events that shareholders should know about. The article provides the title of the filing and its publication date without further details on its content.
Seizures kept falling through 18 months in a Praxis (PRAX) relutrigine follow-up study.
Praxis Precision Medicines, Inc. announced significant positive results from its relutrigine open-label extension data in SCN2A/SCN8A developmental and epileptic encephalopathies, showing an 86% seizure reduction from baseline at 18 months. The company also provided updates on its ulixacaltamide program for essential tremor, including PDUFA dates and plans for expansion into Parkinson's disease, restless legs syndrome, and autism spectrum disorder. Additionally, Praxis outlined its broader pipeline, including next-generation molecules and antisense oligonucleotide programs, emphasizing its commercial readiness for upcoming launches.
Form 8K Praxis Precision Medicines Inc For: 12 November By Investing.com
This article reports that Praxis Precision Medicines Inc. filed a Form 8K on November 12, 2026. The Form 8K is a crucial filing used by public companies to announce major events that shareholders should know about. No specific details about the content of the Form 8K are provided within the article.
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650
Oppenheimer has reiterated its Buy rating on Praxis Precision Medicines (PRAX.US) and maintained its target price of $650. This indicates a continued positive outlook from the firm regarding the pharmaceutical company's prospects.
Raymond James reiterates Strong Buy on Praxis Precision Medicines stock
Raymond James has reiterated a Strong Buy rating on Praxis Precision Medicines Inc. (NASDAQ:PRAX) with a price target of $945.00, citing the company's compelling position in small and mid-cap biotech and potential for two multi-billion-dollar CNS franchises. The firm is optimistic about the Phase 3 success of relutrigine and ulixacaltamide's approval, noting strong commercial readiness. Other analysts, including H.C. Wainwright, also maintain a Buy rating due to the promising pipeline and upcoming catalysts.
Praxis Precision Medicines (PRAX) Stock Looks Rich Against Its Book Value
Praxis Precision Medicines (PRAX) stock has seen significant multi-year gains, prompting investors to question if its current share price aligns with its book value. The company's P/B ratio of 6.9x is higher than the biotech industry average, suggesting it may be overvalued on this metric despite upcoming investor events. Analyst narratives on Simply Wall St offer conflicting views, with a bullish case suggesting it's 71% undervalued based on successful commercial execution of its lead assets, while a bearish case sees it as 77% overvalued due to regulatory hurdles and cost intensity.
PRAX: Praxis Precision Medicines Inc. filed SEC Form 8-K: Results...
Praxis Precision Medicines Inc. reported a Q3 2026 net loss of $94.2 million, an increase from $73.9 million the previous year, primarily due to higher general and administrative costs. The company stated its $1.3 billion in cash and investments are expected to fund operations into 2028. Upcoming FDA decisions for relutrigine (December 27, 2026) and ulixacaltamide (January 29, 2027) are critical for its future outlook.
PRAX: Praxis Precision Medicines Inc. filed SEC Form 8-K: Results...
Praxis Precision Medicines Inc. reported a Q3 2026 net loss of $94.2 million, an increase from $73.9 million a year prior, primarily due to higher general and administrative costs. The company stated its $1.3 billion in cash and investments is expected to fund operations into 2028. Upcoming FDA decisions for relutrigine and ulixacaltamide are critical for the company's future outlook, with target action dates in December 2026 and January 2027, respectively.
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Praxis Precision Medicines reported its third quarter 2026 financial results, including a net loss of $94.2 million, and provided a corporate update. The company's cash and investments of approximately $1.3 billion are projected to fund operations into 2028. Key product candidates, relutrigine and ulixacaltamide, have PDUFA dates set for December 27, 2026, and January 29, 2027, respectively, with topline EMERALD results for relutrigine expected in Q4 2026.
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Praxis Precision Medicines provided a corporate update and reported third-quarter 2026 financial results, highlighting ongoing FDA reviews for relutrigine and ulixacaltamide with PDUFA target action dates in late 2026 and early 2027, respectively. The company expects topline results from the EMERALD study in broad DEEs in Q4 2026 and maintains a strong cash position of approximately $1.3 billion, extending its operational runway into 2028. Praxis is also preparing for an Investor Day on November 12, 2026, to discuss commercial strategies, launch readiness, and pipeline advancements.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. (Nasdaq: PRAX) announced that its Compensation Committee granted restricted stock unit awards covering 23,219 shares of common stock to 59 new non-executive employees on November 2, 2026. These inducement grants, made under the 2024 Inducement Plan, are subject to Nasdaq Listing Rule 5635(c)(4) and will vest in four equal annual installments, contingent upon the employees' continued employment. The company specializes in CNS precision neuroscience biopharmaceuticals, developing therapies for disorders characterized by neuronal excitation-inhibition imbalance.
No sole voting power is reported by Abigail P. Johnson for her Praxis Precision Medicines (PRAX) stake.
FMR LLC and Abigail P. Johnson have each reported beneficial ownership of 2,565,828.27 shares, or 9.2%, of Praxis Precision Medicines (PRAX) common stock. While FMR LLC holds sole voting power over most of its shares, Abigail P. Johnson reported no sole voting power, only sole dispositive power over her shares. This information was disclosed in an amended SCHEDULE 13G/A filing.
Praxis Precision Medicines stock gets 23,219-share hiring grant
Praxis Precision Medicines announced an equity grant of 23,219 restricted stock units to 59 new non-executive employees on November 2, 2026. These awards are part of the company's 2024 Inducement Plan, designed to attract new talent, and will vest in four equal annual installments contingent on continued employment. The company focuses on developing therapies for central nervous system disorders.
(PRAX) Movement Within Algorithmic Entry Frameworks
Praxis Precision Medicines Inc. (NASDAQ: PRAX) shows near-term neutral sentiment but mid and long-term strength, with an exceptional 75.7:1 risk-reward setup targeting a 21.9% gain. AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis highlights key support and resistance levels across different time horizons.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering an aggregate of 23,219 shares of common stock to fifty-nine new non-executive employees on November 2, 2026. These grants were made under the 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), as an inducement for their employment. The restricted stock units will vest in four equal annual installments, contingent on continued employment.
Praxis Precision Medicines stock sets November 12 Investor Day
Praxis Precision Medicines has scheduled an Investor Day for November 12, focusing on the commercial strategy and launch readiness for its late-stage central nervous system pipeline, specifically ulixacaltamide and relutrigine. The company will also report third-quarter results on November 9 and participate in several healthcare investor conferences throughout November. These events provide investors with opportunities to assess the company's progress towards commercialization of its FDA-reviewed programs.
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
Praxis Precision Medicines, Inc. announced its third quarter 2026 financial results will be reported on Monday, November 9, 2026. The company will also host an Investor Day on November 12, 2026, to discuss commercial strategy and pipeline updates, and participate in several investor conferences throughout November. These events aim to provide updates on their CNS precision neuroscience programs, including two programs currently under FDA review.
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
Praxis Precision Medicines, Inc. announced its third-quarter 2026 financial results will be released on November 9, 2026, before market open. The company also detailed an upcoming Investor Day on November 12, 2026, where it will discuss commercial strategy for ulixacaltamide and relutrigine, as well as pipeline updates. Additionally, Praxis will participate in several investor conferences throughout November, including events hosted by Guggenheim Securities, UBS, and Jefferies.
Praxis plans to discuss launch readiness for two medicines under FDA review.
Praxis Precision Medicines (NASDAQ: PRAX) announced it would report third-quarter 2026 financial results on November 9, 2026, and will host an Investor Day on November 12, 2026. During the Investor Day, management will discuss the commercial strategy and launch readiness for two programs currently under FDA review: ulixacaltamide for Essential Tremor and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies. The company will also participate in several investor conferences in November.
Praxis Precision Medicines Announces Third Quarter 2026
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced it will report its Q3 2026 financial results on November 9, 2026. The company will also host an Investor Day on November 12, 2026, to discuss its commercial strategy and pipeline, and will participate in several investor conferences in November.
Praxis Precision Medicines, Inc. Estimates – NASDAQ:PRAX
This article provides an overview of Praxis Precision Medicines, Inc. (NASDAQ: PRAX) financial data and analyst estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates. The platform also visualizes trends over time for both annual and quarterly data.
Praxis Precision Medicines (NasdaqGS:PRAX) Stock Forecast & Analyst Predictions
Praxis Precision Medicines is projected for significant growth, with earnings and revenue expected to increase by 70.9% and 64.1% annually, respectively, and profitability anticipated within three years. Recent analyst updates show mixed revisions, including decreased revenue forecasts for 2026 but an increased consensus price target of around US$610-$620, reflecting ongoing clinical developments and market adjustments. The company is advancing several CNS drug candidates, including ulixacaltamide and relutrigine, which have received FDA designations and are progressing through late-stage trials, despite some recent trial setbacks and regulatory timeline extensions.
UBS Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $706
UBS has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US) and increased the target price to $706. This indicates a strong positive outlook from UBS regarding the company's future performance and stock valuation.
JPMorgan Initiates Praxis Precision Medicines at Overweight With $700 Price Target
JPMorgan has initiated coverage on Praxis Precision Medicines (PRAX) with an "Overweight" rating and a price target of $700. Despite this, the article notes that Praxis Precision Medicines currently has an average rating of "buy" and a mean price target of $650 from analysts. Access to the full MT Newswires article requires a premium subscription.
H.C. Wainwright keeps USD 1,201 target for Praxis Precision Medicines stock
H.C. Wainwright has maintained its USD 1,201 price target for Praxis Precision Medicines (PRAX) as the company approaches key regulatory decisions for its late-stage drugs, ulixacaltamide and relutrigine. UBS also initiated coverage with a Buy rating and a USD 706.00 target. Despite reporting a net loss of USD 83.72 million in Q2 2026, Praxis is preparing for potential drug launches with significant operating expenses and upcoming PDUFA dates in December 2026 and January 2027.
H.C. Wainwright keeps USD 1,201 target for Praxis Precision Medicines stock
H.C. Wainwright has maintained its $1,201 price target for Praxis Precision Medicines (PRAX) stock, following UBS initiating coverage with a $706 target. The company reported a Q2 2026 net loss of $83.72 million and has two upcoming PDUFA decisions for relutrigine and ulixacaltamide. Despite being in a pre-commercial stage, the stock's target valuations are significantly above its current Nasdaq quote, reflecting anticipation of these regulatory milestones.
J.P. Morgan Initiates Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $700
J.P. Morgan has initiated coverage on Praxis Precision Medicines (PRAX.US) with a Buy rating. The firm has set a target price of $700 for the company's stock.
UBS Initiates Praxis Precision Medicines at Buy With $706 Price Target
UBS has initiated coverage on Praxis Precision Medicines with a Buy rating and a significant price target of $706. This suggests a strong bullish outlook from the investment bank regarding the company's future performance and valuation. The high price target indicates UBS believes Praxis Precision Medicines has substantial upside potential.
UBS Initiates Praxis Precision Medicines at Buy With $706 Price Target
UBS has initiated coverage on Praxis Precision Medicines (PRAX) with a "Buy" rating and a price target of $706. The article notes that the company already has an average "Buy" rating from analysts with a mean price target of $647.50. Full details of the analyst's report are behind a paywall.
Responsive Playbooks and the PRAX Inflection
This article analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX) using AI-generated signals, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It provides specific trading strategies—Long, Momentum Breakout, and Short—with entry, target, and stop-loss levels, and emphasizes the elevated downside risk due to the lack of additional long-term support signals. The analysis is based on quantitative research from Stock Traders Daily.
BTIG raised its target for Praxis Precision Medicines stock to USD 826
BTIG has increased its price target for Praxis Precision Medicines (PRAX) stock from USD 810 to USD 826, maintaining a Buy rating. This adjustment reflects the company's strong second-quarter performance, with a smaller loss than expected, and anticipation of key regulatory milestones, particularly for its drug relutrigine, and late-stage pipeline developments. Praxis also reported a robust cash reserve of USD 1.40 billion to support its commercial preparations.
Praxis Precision Medicines Inc (PRAX-Q) Stock Price and News
This article provides stock price information and news updates for Praxis Precision Medicines Inc. (PRAX-Q), a clinical-stage biopharmaceutical company focusing on CNS disorders. It includes real-time stock data, analyst ratings from various firms like Piper Sandler and H.C. Wainwright, and news about the company's Q2 earnings, FDA progress, and clinical trials. The company is based in Cambridge, Mass.
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Prime Medicine, Inc. (PRME)
Analysts from H.C. Wainwright and LifeSci Capital have issued bullish ratings for Praxis Precision Medicines (PRAX) and Prime Medicine, Inc. (PRME), respectively. Praxis Precision Medicines received a Buy rating with a $1201.00 price target, while Prime Medicine, Inc. also received a Buy rating with a $6.00 price target. Both companies show significant upside potential according to current analyst consensus ratings.
FDA extends relutrigine review to December 27, 2026
The FDA has extended the review period for Praxis Precision Medicines' relutrigine NDA by three months to December 27, 2026, following the company's submission of additional sensitivity analyses. This extension is classified as a "major amendment," giving the FDA more time for review, though no new studies or safety concerns were cited. Relutrigine is intended to treat SCN2A and SCN8A developmental and epileptic encephalopathies, conditions for which there are currently no approved treatments.
Needham raises target to $575 after Praxis seizure drug BTD
Needham has raised its price target for Praxis Precision Medicines Inc. to $575 after the FDA granted Breakthrough Therapy Designation (BTD) to elsunersen (PRAX-222) for SCN2A-DEE, a seizure disorder. The BTD was based on Phase 1/2 data showing a 77% reduction in monthly seizures and good tolerability. Praxis is moving forward with a modified pivotal EMBRAVE3 study, currently enrolling patients.
Praxis Precision Medicines stock fell 1.21 percent as Q2 costs rose
Praxis Precision Medicines (PRAX) stock dropped 1.21% as the company reported a Q2 2026 diluted EPS of USD -2.87, beating consensus by USD 0.80, despite operating expenses rising to USD 96.9 million. This increase in costs is attributed to the company's preparations for two potential product launches, with significant cash reserves of USD 1.4 billion to fund operations into 2028. Analyst targets remain elevated, with a Moderate Buy consensus and an average target significantly above the current price, indicating confidence in the company's regulatory timeline and upcoming product approvals.